aTyr Pharma Q2 EPS $(0.23) Beats $(0.25) Estimate
Portfolio Pulse from Benzinga Newsdesk
aTyr Pharma (NASDAQ:ATYR) reported a Q2 EPS loss of $(0.23), beating the analyst consensus estimate of $(0.25) by 8%. This represents a 4.55% increase in losses compared to the same period last year.
August 13, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
aTyr Pharma reported a Q2 EPS loss of $(0.23), which is better than the analyst estimate of $(0.25). However, the loss is 4.55% higher than the same period last year.
The better-than-expected EPS loss is a positive short-term indicator for the stock, although the year-over-year increase in losses may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100